Drug Trial Radar · NCT03594890
Safety and Immune Response of Increasing Doses of OVX836 After Intramuscular or Intranasal Administrations in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Sep 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Jun 12, 2018
Primary completion
Aug 7, 2019
Study completion Aug 7, 2019
Sponsor
- Lead sponsor
- OsivaxIndustry
- Sponsor type
- Industry
- Collaborators
- Aepodia
- First posted
- Jul 20, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 49 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The present study is a first-in-man clinical trial evaluating OVX836, a recombinant broad spectrum vaccine for Influenza. This clinical trial will evaluate the safety and the immune response of increasing doses of OVX836 after intramuscular or intranasal administrations in healthy volunteers.
Conditions
- Influenza
Interventions
OVX836 (Intramuscular)Biological
2 consecutive administrations of OVX836 vaccine at Day 1 and Day 29.
Placebo (Intramuscular)Biological
2 consecutive administrations of placebo at Day 1 and Day 29.
OVX836 (Intranasal)Biological
2 consecutive administrations of OVX836 vaccine at Day 1 and Day 29.
Placebo (Intranasal)Biological
2 consecutive administrations of placebo at Day 1 and Day 29.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Out-of-Range Safety Lab dataTime frame: 28 days after last vaccine administration.
- Safety: Solicited local and systemic reactionsTime frame: 7 days after last vaccine administration.
- Safety: Unsolicited Adverse EventsTime frame: 28 days after last vaccine administration.
- Safety: Serious Adverse EventsTime frame: at end of study visit (i.e. Week 22)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centre for the Evaluation of Vaccination, University of Antwerp
Antwerp, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.